1. Home
  2. MAIA vs FORA Comparison

MAIA vs FORA Comparison

Compare MAIA & FORA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

N/A

Current Price

$1.50

Market Cap

49.3M

Sector

Health Care

ML Signal

N/A

Logo Forian Inc.

FORA

Forian Inc.

N/A

Current Price

$2.08

Market Cap

66.2M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
MAIA
FORA
Founded
2018
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
49.3M
66.2M
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
MAIA
FORA
Price
$1.50
$2.08
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.1M
16.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
29.53
N/A
EPS
N/A
N/A
Revenue
N/A
$20,153,263.00
Revenue This Year
N/A
$51.82
Revenue Next Year
N/A
$7.24
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.87
$1.64
52 Week High
$3.19
$2.71

Technical Indicators

Market Signals
Indicator
MAIA
FORA
Relative Strength Index (RSI) 36.42 46.06
Support Level $1.20 $2.05
Resistance Level $1.69 $2.12
Average True Range (ATR) 0.19 0.02
MACD -0.09 0.00
Stochastic Oscillator 10.19 40.00

Price Performance

Historical Comparison
MAIA
FORA

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

About FORA Forian Inc.

Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.

Share on Social Networks: